Apertura Gene Therapy Unveils Novel Engineered AAV Capsids Targeting Human Transferrin Receptor 1 for Neurological Gene Therapy Delivery

Apertura Gene Therapy unveiled its proprietary engineered Adeno-Associated Virus (AAV) capsids that bind to the human Transferrin Receptor 1 (TfR1). This transportation mechanism mediates the crossing of the blood-brain barrier to enable gene therapy delivery throughout the central nervous system.